SCHEMBL30771364

SCHEMBL30771364

CCOC(=O)C(c1ccccc1)C1CCN(C)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.56
SLC6A3 Q01959 5/20 0.56
SLC6A4 P31645 3/20 0.56
CHRM3 P20309 3/20 0.55
ADRA1A P35348 3/20 0.54
OPRM1 P35372 3/20 0.54
KCNH2 Q12809 3/20 0.54
CYP3A4 P08684 2/20 0.54
TSHR P16473 2/20 0.54
CHRM2 P08172 2/20 0.54
HTR1A P08908 2/20 0.54
ADRA2A P08913 2/20 0.54
CHRM1 P11229 2/20 0.54
DRD1 P21728 2/20 0.54
DRD3 P35462 2/20 0.54
CYP2D6 P10635 2/20 0.54
LMNA P02545 1/20 0.54
CYP1A2 P05177 1/20 0.54
CACNA2D1 P54289 1/20 0.50
CACNA1B Q00975 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28632940 0.88 SLC6A2 (0.67) SLC6A2SLC6A3SLC6A4CHRM3ADRA1A
SCHEMBL10955574 0.87 SLC6A2 (0.70) SLC6A2SLC6A3SLC6A4CHRM3ADRA1A
SCHEMBL8193192 0.84 SLC6A2 (0.65) SLC6A2SLC6A3SLC6A4ADRA1AOPRM1
SCHEMBL26698301 0.83 CHRM3 (0.61) SLC6A2SLC6A3CHRM3ADRA1AOPRM1
SCHEMBL900405 0.81 SLC6A3 (0.57) SLC6A2SLC6A3SLC6A4CHRM3ADRA1A
SCHEMBL13114881 0.80 SLC6A2 (0.49) SLC6A2SLC6A3SLC6A4ADRA1AOPRM1
SCHEMBL26698277 0.80 CHRM3 (0.58) SLC6A2SLC6A3CHRM3ADRA1AOPRM1
SCHEMBL8185506 0.78 HRH1 (0.44) SLC6A2SLC6A3SLC6A4CHRM3ADRA1A
SCHEMBL20924626 0.77 CYP3A4 (0.58) SLC6A2SLC6A3SLC6A4CHRM3ADRA1A
SCHEMBL13114880 0.77 MAPT (0.65) HTR1ALMNAALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-11-13 US disclosed
EP-4532484-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-04-09 EP disclosed
CN-119173509-A ROCK inhibitors and uses thereof 迪哲(江苏)医药股份有限公司 2024-12-20 CN disclosed
WO-2023226965-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF ROCK1, ROCK2, RHOA SLC6A2 2961/4885SLC6A3 2540/4885SLC6A4 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.